Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region

Clinical Hematology International · Published 2025-05-08 · DOI 10.46989/001c.137860

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.46989/001c.137860

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Incidence and impact of other malignancies after immunochemotherapy by fludarabine, cyclophosphamide, and rituximab as frontline treatment for chronic lymphocytic leukemia: A single-center retrospective study. · Clinical Hematology International · 2025 · Same journal
• Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma · Clinical Hematology International · 2024 · Same journal
• Role of cytomegalovirus reactivation on relapse after allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia · Clinical Hematology International · 2024 · Same journal
• Factor XIII Deficiency: A Review of Biology, Testing, and Treatment · Clinical Hematology International · 2026 · Same journal
• Disseminated adenovirus infection following CAR T-cell therapy: Early-onset presentation in a patient with relapsed refractory mantle cell lymphoma · Clinical Hematology International · 2026 · Same journal
• Current landscape of academic and point of care CAR-T cell therapy in low-middle income countries · Clinical Hematology International · 2026 · Same journal
• Allogeneic and other innovative chimeric antigen receptor platforms · Clinical Hematology International · 2024 · Same journal
• Untangling the clonal architecture in a case of acute myeloid leukaemia with multiple cytogenetically unrelated clones · Clinical Hematology International · 2024 · Same journal
• How I treat newly diagnosed acute lymphoblastic leukemia · Clinical Hematology International · 2024 · Same journal
• Large intramuscular hematoma due to acquired Factor VIII inhibitors in post Polycythemia Vera-Myelofibrosis · Clinical Hematology International · 2025 · Same journal